<DOC>
	<DOCNO>NCT01769196</DOCNO>
	<brief_summary>This study evaluate efficacy safety simtuzumab ( GS-6624 ) adult idiopathic pulmonary fibrosis .</brief_summary>
	<brief_title>A Phase 2 Study See Simtuzumab ( GS-6624 ) Safe Works Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Male female subject 45 85 year age Definite IPF within 3 year prior screen Be able walk least 50 meter Significant disease IPF Obstructive lung disease Aortic aneurysm great equal 3.5 cm diameter Treatment immunosuppressive , cytotoxic , antifibrotic drug &lt; 28 day prior randomization permit . Nacetylcysteine permit provide individual stable dose &gt; 4 week prior screen Concomitant use pirfenidone nintedanib must accordance approve prescribing instruction country site locate Individuals actively list lung transplant exclude . However individual transplant center long wait time ( great 1 year ) may permit enter study discussion Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
</DOC>